Guggenheim raised the firm’s price target on Tenet Healthcare (THC) to $257 from $238 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare Board Member Resigns, Board Size Reduced
- Tenet Healthcare price target raised to $240 from $229 at Barclays
- Tenet Healthcare Issues $2.25 Billion in New Notes
- Tenet Healthcare price target raised to $230 from $200 at JPMorgan
- Tenet Healthcare price target raised to $252 from $238 at Wells Fargo